Teneligliptin hydrobromide hydrate is primarily used in the treatment of type 2 diabetes mellitus. It functions as a dipeptidyl peptidase-4 (DPP-4) inhibitor, which helps regulate blood sugar levels by increasing the release of insulin and decreasing the production of glucagon. This medication is often prescribed when diet, exercise, and other antidiabetic drugs do not provide adequate glycemic control. It is typically administered orally and is known for its efficacy in improving postprandial and fasting glucose levels. Additionally, it is often preferred due to its lower risk of causing hypoglycemia compared to some other diabetes medications. It may be used alone or in combination with other antidiabetic agents, depending on the patient's condition and treatment plan.